

Neo-Adjuvant

UCI 13-56 ****SUSPENDED****

A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemo radiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only (Nangia)

UCI 16-72 Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Nangia)

UCI 17-33** A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity (Nangia)

NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Nangia)

Metastatic


RTOG-1216 ****SUSPENDED****

Randomized Phase II/III Trial of Surgery & Postoperative Radiation Delivered With Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (Nangia)

UCI 16-50 **SUSPENDED****** Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics & Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Pts With Advanced Solid Malignancies & Subsequently Comparing AZD9150 & AZD5069 Both as Monotherapy & in Combination With MEDI4736 as Second Line Treatment in Pts With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Nangia)

RTOG-0920 Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (Nangia)

UCI 16-75** An Open-label, Single-arm, Multi-institutional Phase II Trial of Avelumab for Recurrent, Metastatic Nasopharyngeal Carcinoma (Nangia)



Multiple Disease Sites

UCI 13-49 Open-Label Dose-Escalation Trial to Evaluate the Safety, PK, and PD of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies (**Ou**)

UCI 16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (**Ou**)

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) (**Seery**)

UCI 17-50 ** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

ECOG-EAY131** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

Correlative

UCI 14-36 A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (**Seery**)

UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (**Nelson**)

UCI 16-01 (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer (**Nelson**)